Article
Cell-type specific effects of SARS-CoV-2 P252L mutation on nirmatrelvir sensitivity.
Antiviral research - 1 Jul 2026
Loison Sheryline, Chabert Mehdi, Gensous Constant, Constant Samuel, Huang Song, Tapparel Caroline, Clément Sophie
Abstract excerpt
The SARS-CoV-2 main protease (NSP5) is the target of the FDA approved Nirmatrelvir (NTV) antiviral. Substitutions in NSP5, such as the P252L mutation, have been reported in clinical isolates and raise questions regarding its potential role in drug resistance. Here, we show that the P252L effect on NTV susceptibility is dependent on the culture model. The mutation arises spontaneously in VeroE6 cells without...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
